drugset / Trial / NCT01106131

Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin

NCT01106131

Phase 3 Completed 253 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to prove effect of glucose reduction that CKD-501 and metformin combination treatment group is non inferiority compare to pioglitazone and metformin combination.

Timeline

Start
2010-05
Primary completion
2012-04
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Lobeglitazone Small molecule 0.5 mg Oral
Comparator Pioglitazone Small molecule 15 mg Oral